JACOBSON PHARMA (02633) announces its interim performance with a net profit attributable to shareholders of 142 million Hong Kong dollars, representing a year-on-year increase of 1.24%.
Jacobson Pharmaceutical (02633) released its mid-term performance in 2025, with the group achieving a revenue of HKD 7.67 billion during the period.
Jacobson Pharma (02633) announced its mid-year performance for 2025. The group achieved a revenue of HK$767 million, a decrease of 5.36% compared to the same period last year. The net profit attributable to equity holders of the company was HK$142 million, an increase of 1.24% year-on-year. Basic earnings per share were 7.12 HK cents. The mid-year dividend per share was 4.25 HK cents.
Related Articles
Northeast: Music ecosystem giant NETEASE MUSIC (09899) benefits from rapid industry growth.
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Northeast: Music ecosystem giant NETEASE MUSIC (09899) benefits from rapid industry growth.
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
